A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study Comparing FX006 to Commercially Available Triamcinolone Acetonide Injectable Suspension in Patients With Osteoarthritis of the Knee.

Trial Profile

A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study Comparing FX006 to Commercially Available Triamcinolone Acetonide Injectable Suspension in Patients With Osteoarthritis of the Knee.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Triamcinolone (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Flexion Therapeutics
  • Most Recent Events

    • 02 Nov 2017 According to a Flexion Therapeutics media release, pooled analysis data of this and two other trials (see CT profiles 243924 and 234469) will be presented at the 2017 American College of Rheumatology (ACR) Annual Meeting.
    • 07 Sep 2017 According to a Flexion Therapeutics media release, post-hoc pooled analysis of this and two other trials (see CT profiles 243924 and 234469) will be presented at PAINWeek 2017.
    • 24 May 2017 Results assessing cost-effectiveness of Extended-Release Triamcinolone Acetonide from the clinical outcome data of three randomised trials (NCT01487161, NCT02116972, NCT02357459; n=324) presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top